ASH in Cuba: Unmasking Challenges and Opportunities in Hematology
Following ASH's executive committee's retreat in Havana, Cuba, Dr. Gotlib discusses lessons, challenges and opportunities for hematologists and the community, with commenta
Core Circadian Clock Genes Regulate Leukemia Stem Cells
Drs. Abdel-Wahab and Taylor look at a study about the use of core circadian clock genes in anti-leukemic therapy.
Following ASH's executive committee's retreat in Cuba, Dr. Gotlib discusses lessons, challenges and opportunities for hematologists and the community.
Dr. DeBaun covers a study for an antiplatelet agent to reduce severity and frequency of acute vaso-occlusive pain in SCD patients.
Dr. Raetz compares two drugs for the induction phase of treatment of childhood ALL.
July/August 2016 Volume 13, Issue 4
View all Features articles
View all Diffusion articles
Dr. Charles Abrams talks about the ASH executive committee's experience in Havana, Cuba during this year's retreat.
View all president's column articles
View all Ask the Hematologist articles
View all Op-Ed articles
View all Mini Review articles
The Centers for Medicare and Medicaid Services (CMS) released the annual set of proposals governing payments for services provided to patients admitted to the hospital, commonly referred to as the hospital inpatient prospective payment system (IPPS). ASH explores how this will affect hematologists.
As part of the American Society of Hematology’s (ASH)
multifaceted initiative to address the burden of sickle cell disease, ASH is in
the process of working with stakeholders to improve access to care for
individuals with sickle cell disease.
Included in this effort is
On March 8, 2016, the Center for Medicare and Medicaid Services (CMS) proposed a new experiment in payment rates for physician-administered drugs such as chemotherapy. This plan would change the current formula for drug payment so that payments for expensive drugs are reduced in certain areas of the country. In a second phase, CMS would be able to adopt certain tools to further adjust pricing for drugs.
ASH submitted comments to the National Heart, Lung and Blood Institute (NHLBI) on its recently released draft strategic research priorities that will inform the Institute’s policy and funding decisions for the next several years. ASH’s comments were developed based on the ASH Agenda for Hematology Research and input from members of the ASH Committee on Scientific Affairs and ASH Scientific Committees.
AMERICAN SOCIETY OF HEMATOLOGY
2021 L Street NW, Suite 900, Washington, DC 20036
Phone 202-776-0544 | Fax 202-776-0545
by American Society of Hematology